Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma

Inclusion Criteria: * Histologically confirmed classical Hodgkin Lymphoma or Lymphocyte Predominant Hodgkin Lymphoma with progressive disease during or at the end of the previous therapy, as defined by the IWG criteria. * Patient must have nodular sclerosing, lymphocyte depleted, or mixed cellularity Hodgkin Lymphoma (Classical Hodgkin Lymphoma), or Lymphocyte predominant Hodgkin Lymphoma. * Baseline measurements and evaluations must be obtained within 4 weeks of registration to the study. * Abnormal PET scans will not constitute evaluable disease, unless verified by CT scan or other appropriate imaging. * A clearly defined, bidimensionally measurable lymph node or tumor mass measuring at least 2 cm in diameter on a CT scan. * Patient should have had at least one line of prior chemotherapy. Patients relapsing after treatment with radiation therapy alone are not eligible. * Age \> than or equal to 18 years. * Both men and women and members of all races and ethnic groups are eligible for this trial. * Women must not be pregnant or breast-feeding due to lack of information about the safety of administration of Temsirolimus in pregnant and lactating patients. All females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy. * Women of childbearing potential and sexually active males are strongly advised to use an accepted and effective method of pregnancy prevention. * Patient must have a SWOG performance status between 0-2. * Patient must have no prior treatment with an m-TOR inhibitor. * Patient must not have active infections at the time of registration. * Laboratory studies should be obtained within two weeks of study registration except where noted otherwise. Allowable laboratory values are listed below: * Absolute neutrophil count \> than or equal 1,000/mm3 * Hemoglobin \> than or equal 8 gm/dL * Platelets \> than or equal 75,000/mm3 * Serum creatinine \< than or equal to two times the upper limit of normal. Creatinine should be measured within seven days of registration. * Total serum bilirubin \< than or equal to ≤ 1.5 times the upper limit of normal. Total bilirubin should be measured within seven days of registration. * AST (SGOT) \< than or equal to 3 times the upper limit of normal. * ALT (SGPT) \< than or equal to 3 times the upper limit of normal. * Fasting total cholesterol \< than or equal to 350 mg/dL. * Fasting triglyceride level \< than or equal to 400 mg/dL. * Patient must have a life expectancy of three months. Exclusion Criteria: * Patient must not have received prior allogeneic stem cell transplantation. Prior autologous stem cell transplantation more than six months prior to registration is acceptable. * Patient must not have received prior chemotherapy, biologic therapy or radiation within three weeks prior to registration, and should have recovered from toxicities of prior therapy (to Grade 0 or 1). * Patient must not have evidence of active CNS disease. * Patient must not have an uncontrolled comorbid disease, including hyperlipidemia, hypertriglyceridemia, diabetes mellitus, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia * Patient must not have a psychiatric illness or social situation that would limit compliance with study requirements. * Patient must have a life expectancy of three months.